SCHEMBL6311358

SCHEMBL6311358

CCOC(=O)c1ccc(N=C=S)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.44
STS P08842 1/20 0.41
MAPT P10636 2/20 0.41
GRM6 O15303 1/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 1/20 0.40
PDE4B Q07343 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059428 0.84 MAPK1 (0.54) CA12CA1CA2CA7CA9
SCHEMBL6575685 0.82 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL1457515 0.77 MAPT (0.56) CA12CA1CA2CA7CA9
SCHEMBL12394100 0.77 L3MBTL1 (0.52) ESR1LMNACYP1A2CYP3A4STS
SCHEMBL659139 0.75 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL29800427 0.75 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL811649 0.75 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL3376117 0.75 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL1091973 0.75 MAPT (0.55) CA12CA1CA2CA7CA9
SCHEMBL152572 0.73 CA12 (0.59) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176773-A1 Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and method for their use AGOURON PHARMACEUTICALS, INC. 2005-08-11 US disclosed
US-20050038078-A1 Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. 2005-02-17 US disclosed
US-20050026966-A1 Process and chiral amine intermediates useful for preparation of antiproliferative 2,4-diaminothiazole amide compounds AGOURON PHARMACEUTICALS, INC. 2005-02-03 US disclosed
US-20050026966-A1 Process and chiral amine intermediates useful for preparation of antiproliferative 2,4-diaminothiazole amide compounds AGOURON PHARMACEUTICALS, INC. 2005-02-03 US disclosed
US-20050026966-A1 Process and chiral amine intermediates useful for preparation of antiproliferative 2,4-diaminothiazole amide compounds AGOURON PHARMACEUTICALS, INC. 2005-02-03 US disclosed
WO-2004014904-A1 ANTIPROLIFERATIVE 2-(HETEROARYL)-AMINOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE PFIZER INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176773-A1 Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and method for their use CDK2, MKI67, CCNK CA12 4734/4885CA1 4633/4885CA2 2605/4885
US-20050038078-A1 Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use CDK2, CCNK, MKI67 CA12 4749/4885CA1 4617/4885CA2 2662/4885
US-20050026966-A1 Process and chiral amine intermediates useful for preparation of antiproliferative 2,4-diaminothiazole amide compounds DDC, TK1, AADAT CA12 3626/4885CA1 2753/4885CA2 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.